Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat

Journal of Hypertension

Volumn 28, Issue 7, 2010, Pages 1566-1573

  Dupuis, François ^a   Vincent, Jean Martin ^a   Limiñana, Patrick ^a   Chillon, Jean Marc ^b   Capdeville Atkinson, Christine ^a   Atkinson, Jeffrey ^a  

^a UNIVERSITÉ DE LORRAINE   (France)

^b UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

Author keywords

cerebral blood flow; hypertension; pharmacology; pial vessels

Indexed keywords

CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE; POTASSIUM; RAMIPRIL; RENIN; TELMISARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTICLE; BLOOD GAS; BLOOD PRESSURE REGULATION; BRAIN ARTERY; BRAIN CIRCULATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; DRUG TOLERABILITY; ENZYME ACTIVITY; FLUID INTAKE; FOOD INTAKE; GROWTH RATE; HEART RATE; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; OPTIMAL DRUG DOSE; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT;

EID: 77954366329     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e328339f1f3     Document Type: Article

References (26)

1. Rizzoni D, De Ciuceis C, Porteri E, Paiardi S, Boari GE, Mortini P, et al. Altered structure of small cerebral arteries in patients with essential hypertension. J Hypertens 2009; 27:838-845.
2. Dupuis F, Atkinson J, Limiñana P, Chillon JM. Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats. J Hypertens 2005; 23:1061-1066.
3. Choki JI, Yamaguchi T, Takeya Y, Morotomi Y, Omae T. Effect of carotid artery ligation on regional cerebral blood flow in normotensive and spontaneously hypertensive rats. Stroke 1977; 8:374-379.
4. Capdeville C, el Bouhtoury F, Parache RM, Boulu RG, Guillou J, Atkinson J. The angiotensin I converting enzyme inhibitors, captopril and Wy-44 655 attenuate the consequences of cerebral ischemia in renovascular hypertensive rats. Life Sci 1990; 47:539-546.
5. Dupuis F, Atkinson J, Limiñana P, Chillon JM. Captopril improves cerebrovascular structure and function in old hypertensive rats. Br J Pharmacol 2005; 144:349-356.
6. Pfeffer MA, McMurray JJ, Velazquez EJ, Rouleau JL, Kober L, Maggioni AP, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349:1893-1906.
7. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358:1547-1559.
8. Schrader J, Luders S, Kulschewski A, Berger J, Zidek W, Treib J, et al. The ACCESS Study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke 2003; 34:1699-1703.
9. Schrader J, Luders S, Kulschewski A, Hammersen F, Plate K, Berger J, et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES). Stroke 2005; 36:1218-1226.
10. McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362:767-771. (Pubitemid 37093916)
11. Unger T. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. Am J Cardiol 2003; 91:28G-34G.
12. Vincent JM, Kwan YW, Chan SL, Perrin-Sarrado C, Atkinson J, Chillon JM. Constrictor and dilator effects of angiotensin II on cerebral arterioles. Stroke 2005; 36:2691-2695.
13. Baumbach GL, Dobrin PB, Hart MN, Heistad DD. Mechanics of cerebral arterioles in hypertensive rats. Circ Res 1988; 62:56-64.
14. Kontos HA, Wei EP, Navari RM, Levasseur JE, Rosenblum WI, Patterson JL. Responses of cerebral arteries and arterioles to acute hypotension and hypertension. Am J Physiol 1978; 234:H371-H383.
15. Chillon JM, Baumbach GL. Effects of an angiotensin-converting enzyme inhibitor and a b-blocker on cerebral arterioles in rats. Hypertension 1999; 33:856-861.
16. Chan SL, Capdeville-Atkinson C, Atkinson J. Red wine polyphenols improve endothelium-dependent dilation in rat cerebral arterioles. J Cardiovasc Pharmacol 2008; 51:553-558.
17. Heinemann A, Wachter CH, Peskar BA, Holzer P. Dilatation by angiotensin II of the rat femoral arterial bed in vivo via pressure/flow-induced release of nitric oxide and prostaglandins. Br J Pharmacol 1997; 122:975-984.
18. Mulvany MJ, Baumbach GL, Aalkjaer C, Heagerty AM, Korsgaard N, Schiffrin EL, Heistad DD. Vascular remodeling [letter to the editor]. Hypertension 1996; 28:505-506.
19. Baumbach GL, Heistad DD. Remodeling of cerebral arterioles in chronic hypertension. Hypertension 1989; 13:968-972.
20. Campbell DJ, Kladis A, Valentijn AJ. Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme. J Cardiovasc Pharmacol 1995; 26:233-240.
21. Gigante B, Piras O, De Paolis P, Porcellini A, Natale A, Volpe M. Role of the angiotensin II AT2-subtype receptors in the blood pressure-lowering effect of losartan in salt-restricted rats. J Hypertens 1998; 16:2039-2043.
22. Brassard P, Amiri F, Schiffrin EL. Combined angiotensin II type 1 and type 2 receptor blockade on vascular remodeling and matrix met alloproteinases in resistance arteries. Hypertension 2005; 46:598-606.
23. Brassard P, Amiri F, Thibault G, Schiffrin EL. Role of angiotensin type-1 and angiotensin type-2 receptors in the expression of vascular integrins in angiotensin II-infused rats. Hypertension 2006; 47:122-127.
24. Funder J. Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol 2001; 28:1002-1006.
25. Dupuis F, Atkinson J, Limiñ ana P, Chillon JM. Spironolactone and eutrophic inward remodelling in cerebral arterioles of spontaneously hypertensive rats [abstract]. Fund Clin Pharmacol 2005; 19:207.
26. Phillips CO, Kashani A, Ko DK, Francis G, Krumholz HM. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials. Arch Intern Med 2007; 167:1930-1936.